Company Information

  

Address: 15 CROSBY DRIVE  
City: BEDFORD 
State: MA 
Zip Code: 01730 
Telephone: 781-895-3235 

Description of Business

Primary SIC Code: 2834
(As filed with the SEC)  

We are a biopharmaceutical company focused on the development and commercialization of innovative therapies for diseases and conditions of the eye using our proprietary hydrogel platform technology. Our bioresorbable hydrogel-based drug product candidates are designed to provide extended delivery of therapeutic agents to the eye. Our lead product candidates are DEXTENZA (dexamethasone insert), for the treatment of post-surgical ocular inflammation and pain, allergic conjunctivitis and dry eye disease, and OTX-TP, for the treatment of glaucoma and ocular hypertension, which are extended-delivery, drug-eluting inserts that are placed into the canaliculus through a natural opening called the punctum located in the inner portion of the eyelid near the nose. Our intracanalicular inserts combine our hydrogel technology with U.S. Food and Drug Administration, or FDA, approved therapeutic agents with the goal of providing extended delivery of drug to the eye.  ... More ...  

Per Share Overview

Date 12-mos Rolling EPS Dividend P/E Ratio
06/2017-2.12NAN/E
03/2017-1.94NAN/E
12/2016-1.80NAN/E
09/2016-1.72NAN/E
06/2016-1.80NAN/E
03/2016-1.80NAN/E
12/2015-1.71NAN/E
09/2015-1.04NAN/E

Key Financial Ratios and Statistics

FYE: 12/31

Profitability 2016 Leverage 2016
Net Inc/Comm Equity-0.20Total Liab/Total Assets0.31
Net Inc/Total Assets-0.60Total Liab/Inv Cap0.35
Net Inc/Inv Cap-0.69Total Liab/Comm Equity0.10
Pretax Inc/Net Sales-23.69Interest Coverage Ratio-25.61
Net Inc/Net Sales-23.69Curr Debt/Equity0.03
Cash Flow/Net Sales-18.02LTD/Equity0.27
SG&A/NetSales9.38Total Debt/Equity0.30
Asset Utilization   Liquidity  
Net Receivables Turnover8.52Quick Ratio8.41
Inventory Turnover3.59Current Ratio8.42
Inventory Day Sales0.01Net Rec/Curr Assets0.00
Net Sales/Work Cap0.03Inv/Curr Assets0.00
Net Sales/PP&E0.57  

Income Statement (Millions)

  6/30/2017 3/31/2017 12/31/2016 9/30/2016
Total Revenues(Net Sales) 0.44 0.48 0.51 0.48
Cost of Goods Sold 0.10 0.12 0.13 0.11
Selling & Admin Exps 10.56 9.30 5.53 3.92
Operating Income -18.34 -15.67 -12.47 -9.24
Interest Exp 0.47 0.44 0.42 0.43
Pretax Income -18.69 -16.02 -12.82 -9.60
Other Income 0.11 0.09 0.07 0.07
Net Income Bef Extraordinary ... NA NA NA NA
Net Income -18.69 -16.02 -12.82 -9.60

Balance Sheet (Millions)

Assets 6/30/2017 3/31/2017 12/31/2016 9/30/2016
Cash & Short Term Investments 66.05 80.38 68.15 75.75
Receivables - Total 0.21 0.24 0.25 0.24
Inventories - Total 0.09 0.10 0.11 0.13
Total Current Assets 68.33 83.28 69.90 76.82
Net Property, Plant & Equipment 9.62 5.69 3.31 3.80
Total Assets 79.68 90.70 74.94 82.35
Liabilities        
Accounts Payable 10.69 7.76 6.75 4.47
Debt in Current Liabilities 2.44 0.90 1.55 3.77
Total Current Liabilities 13.13 8.66 8.30 8.24
Long-Term Debt 15.37 16.82 14.09 11.78
Total Liabilities 31.65 26.79 22.93 20.05
Stockholder's Equity        
Minority Interest NA NA NA NA
Preferred Stock 0.00 0.00 0.00 0.00
Common Stock 0.00 0.00 0.00 0.00
Retained Earnings -208.60 -189.90 -173.88 -161.06
Treasury Stock NA NA NA NA
Total Stockholders' Equity 48.03 63.91 52.01 62.29
Total Liabilities and Stockholders' Equity 79.68 90.70 74.94 82.35

Cash Flow Summary (Millions)

Categories 6/30/2017 3/31/2017 12/31/2016 9/30/2016
Net Cash Provided by Operating Activities -11.13 -14.58 -7.61 -7.33
Net Cash Provided by Investing Activities 18.70 7.85 -12.38 11.32
Net Cash Provided by Financing Activities 0.80 28.48 0.69 0.08

Annual Summary Data (Millions)

Year Sales Net Income EPS
12/20120.01-14.09--
12/20130.00-13.32--
12/20140.77-28.65-2.69
12/20151.75-39.75-1.71
12/20161.89-44.70-1.80
Growth Rates270.63----

Stock Ownership

Type Date(Q,M) No. Owners Shares Held (000s) % Own
Institutional09/30/178715,45353.18




Report Date : 10/16/2017

Powered By Edgar Online © 2017EDGAR®Online, a division of Donnelley Financial Solutions. EDGAR® is a federally registered trademark of the U.S. Securities and Exchange Commission. EDGAR Online is not affiliated with or approved by the U.S. Securities and Exchange Commission.